425: Waters Corporation and BD Biosciences & Diagnostic Solutions Announce $17.5 Billion Combination to Create Life Science and Diagnostics Leader

Waters Corporation and Becton, Dickinson & Company's Biosciences & Diagnostic Solutions business will combine in a $17.5 billion Reverse Morris Trust transaction, aiming to create a leading life science and diagnostics company with significant market expansion and synergy potential.

Summary

• Waters Corporation and Becton, Dickinson & Company (BD) have entered into a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters, valued at approximately $17.5 billion.
• The transaction is structured as a tax-efficient Reverse Morris Trust, where BD's Biosciences & Diagnostic Solutions business will be spun off to BD shareholders and simultaneously merged with a wholly owned subsidiary of Waters.
• The combined company is projected to have pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion.
• The combination is expected to double Waters' total addressable market (TAM) to approximately $40 billion, with an anticipated annual growth rate of 5-7%.
• Annual recurring revenue for the combined entity is expected to exceed 70%, with over 80% of revenue derived from iconic market-leading brands.
• Significant annualized EBITDA synergies of approximately $345 million are anticipated by 2030, comprising $200 million in cost synergies by year three post-closing and $290 million in revenue synergies by year five.
• The transaction is expected to be accretive to adjusted EPS in the first year post-closing.
• BD will receive a cash distribution of approximately $4 billion prior to completion, and Waters is expected to assume approximately $4 billion of incremental debt, resulting in a net-debt-to-adjusted EBITDA leverage ratio of 2.3x at closing.
• The transaction has been unanimously approved by the Boards of Directors of both Waters and BD and is expected to close around the end of the first quarter of calendar year 2026, subject to regulatory and Waters shareholder approvals.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook on the proposed transaction, emphasizing significant strategic fit, substantial financial synergies, market expansion, and strong future growth projections. The language used by management and the detailed financial benefits suggest a very optimistic sentiment regarding the combination's potential.

Positives

• Creates an innovative life science and diagnostics leader with pioneering technologies and an industry-leading financial outlook.
• Doubles Waters' total addressable market to approximately $40 billion, with a consistent 5-7% annual growth rate.
• Increases annual recurring revenue to over 70% and ensures over 80% of revenue comes from iconic market-leading brands, enhancing growth stability.
• Anticipates substantial annualized EBITDA synergies of approximately $345 million by 2030, including $200 million in cost synergies by year three and $290 million in revenue synergies by year five.
• Delivers an industry-leading financial outlook with mid-to-high single-digit revenue growth, approximately 500 basis points of adjusted operating margin expansion, and mid-teens annualized adjusted EPS growth expected over five years.
• The transaction is expected to be accretive to adjusted EPS in the first year post-closing.
• Combines complementary technologies (liquid chromatography, mass spectrometry, flow cytometry, diagnostic solutions) to serve high-volume testing in attractive and regulated end-markets.
• Accelerates Waters' expansion into high-growth adjacent end-markets such as bioseparations, bioanalytical characterization, and multiplex diagnostics.
• Leverages Waters' proven execution model to unlock the full potential of BD's Biosciences & Diagnostic Solutions business, including instrument replacement, service plan attachment, and e-commerce adoption.
• The transaction is structured as a generally tax-free Reverse Morris Trust for U.S. federal income tax purposes to BD and BD's shareholders.

Risks

• One or more closing conditions, including certain regulatory approvals, may not be satisfied or waived on a timely basis or at all, potentially leading to prohibition, delay, or refusal of approval by governmental entities, or requiring conditions, limitations, or restrictions.
• The required approval by Waters' stockholders may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected by Waters, BD, and SpinCo, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty exists regarding the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delays in completing the transaction or integrating the businesses of Waters and SpinCo, on the expected timeframe or at all.
• The combined company may face difficulties in implementing its business strategy.
• Difficulties and delays may occur in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification, and liability.
• Evolving legal, regulatory, and tax regimes could impact the transaction or combined operations.
• Changes in general economic and/or industry-specific conditions or any volatility resulting from the imposition of and changing policies around tariffs.
• Actions by third parties, including government agencies, could affect the transaction.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• Greater than expected difficulty in separating the business of SpinCo from the other businesses of BD.
• Disruption of management time from ongoing business operations due to the pendency of the proposed transaction.
• Other effects of the pendency of the proposed transaction on the relationship of any of the parties to the transaction with their employees, customers, suppliers, or other counterparties.
• The credit ratings of the combined company could decline following the proposed transaction.
• The announcement or consummation of the proposed transaction could have a negative effect on the market price of the capital stock of Waters and BD or on Waters and BD's operating results.

Future Outlook

The combined company is expected to achieve mid-to-high single-digit revenue growth and mid-teens adjusted EPS growth on an annualized basis between 2025 and 2030. By 2030, the pro forma combined company is projected to reach approximately $9 billion in revenue, $3.3 billion in adjusted EBITDA, and an adjusted operating margin of 32%. The transaction is anticipated to be accretive to adjusted EPS in the first year post-closing.

Management Comments

• Flemming Ornskov, M.D., M.P.H., Chairman, Waters, stated: 'This transaction marks a pivotal milestone in Waters' transformation journey as we embark on a new chapter of growth and value creation. As the Board of Directors evaluated this opportunity throughout the process, it became evident that combining with BD's Biosciences & Diagnostic Solutions business is an excellent strategic fit with complementary strengths. We are confident that this combination will accelerate our strategy in multiple high-growth markets and deliver substantial nearand long-term value to our shareholders.'
• Udit Batra, Ph.D., President and Chief Executive Officer, Waters, commented: 'Waters' transformation, marked by strong commercial execution and revitalized innovation, positions us well for this exciting next chapter. We see tremendous opportunity to immediately apply our expertise in instrument replacement, service plan attachment, and eCommerce expansion, and realize the full potential of the flow cytometry and specialty diagnostics portfolios. The combination doubles our accessible market to approximately $40 billion and allows us to accelerate value creation in multiple high-growth adjacencies such as bioseparations, bioanalytical characterization, and multiplex diagnostics, while increasing the ratio of our annually recurring revenues. We are bringing together two pioneering organizations with a rich history of delivering breakthrough innovations driven by strong R&D investment and a common customer-centric culture. I look forward to welcoming our talented and like-minded colleagues from BD's Biosciences & Diagnostic Solutions business and leading the collective organization. Together, we will work to make this combination a resounding success for our stakeholders and deliver significant value for shareholders.'
• Tom Polen, Chairman, CEO and President, BD, remarked: 'We are bringing together complementary portfolios and channels that create an industry-leading life science and diagnostics company. We see an incredible opportunity to leverage both companies' commitments to unparalleled innovation, technology, and commercial presence to serve attractive high-growth end-markets, while simultaneously unlocking multiple new growth vectors. We couldn't be more confident that the combined company, under Udit's leadership, represents the best path to create substantial value for shareholders. Waters offers the right cultural fit for our Biosciences & Diagnostic Solutions associates to flourish and continue their legacy of developing new-to-world, innovative solutions that make a meaningful impact on global healthcare. This transaction is an important milestone for BD, as it enhances our strategic focus as a leading medical technology company. BD is committed to unlocking long-term value through continued investment in our strong innovation pipeline, and operational and commercial excellence that will drive durable and profitable growth.'

Industry Context

This strategic combination positions the new entity as a formidable leader in the life science tools and diagnostics industry, expanding its presence in high-growth adjacencies like bioseparations, bioanalytical characterization, and multiplex diagnostics. By integrating Waters' expertise in liquid chromatography and mass spectrometry with BD's strengths in flow cytometry and diagnostic solutions, the combined company aims to capture a larger share of the regulated, high-volume testing market. The focus on increasing recurring revenue and leveraging established execution models aligns with broader industry trends emphasizing stable, predictable revenue streams and operational efficiency in the highly competitive life sciences sector.

Comparison to Industry Standards

• The combined company's pro forma expected 2025 adjusted EBITDA margin of 27% is projected to expand by approximately 500 basis points, reaching 32% by 2030, which is described as an 'industry-leading financial outlook'.
• Waters' standalone adjusted EBITDA margin for CY 2024 was 37%, significantly higher than the peer average of 27% (peers include A, AVTR, DHR, RVTY, TMO).
• Waters' standalone Free Cash Flow as a percentage of revenue for CY 2024 was 25%, also higher than the peer average of 18%.
• The combined company's projected mid-to-high single-digit revenue growth and mid-teens adjusted EPS growth are presented as 'industry-leading' compared to general industry benchmarks.
• The transaction multiple of 13.8x (with run-rate synergies) and 18.9x (on a pre-synergy basis) for CY2025E provides a benchmark for valuation within the life science tools and diagnostics sector.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders (Waters):** Expected to own approximately 60.8% of the combined company, benefiting from significant value creation, rapid adjusted EPS accretion, and an industry-leading financial outlook.
• **Shareholders (BD):** Expected to own approximately 39.2% of the combined company and BD will receive a cash distribution of approximately $4 billion, with a commitment to use at least half for share repurchases, enhancing capital allocation.
• **Employees (Waters & BD Biosciences & Diagnostic Solutions):** The combined company will have approximately 16,000 employees. Management emphasizes a common customer-centric culture and a commitment to associates flourishing, suggesting potential for new opportunities within the larger entity.
• **Customers:** Expected to benefit from best-in-class liquid chromatography, mass spectrometry, flow cytometry, and diagnostic solutions, enhanced market access, improved service support, accelerated menu expansion, and automation for multiplex diagnostics.
• **Suppliers & Other Counterparties:** The pendency of the transaction carries a risk of disruption to business, contractual, and operational relationships.

Next Steps

• Waters and BD will host a joint conference call and webcast on July 14, 2025, to discuss the Proposed Transaction.
• Waters, SpinCo, and BD intend to file relevant materials with the SEC, including a registration statement on Form S-4 by Waters (including a proxy statement/prospectus) and a registration statement on Form 10 by SpinCo (serving as an information statement/prospectus).
• The transaction is subject to receipt of required regulatory approvals and Waters shareholder approval.
• The transaction is expected to close around the end of the first quarter of calendar year 2026.
• Key leadership roles for the combined entity, beyond the CEO and CFO, will be announced at a later date.
• Up to two BD designees will join the Waters Board of Directors upon closing.

Key Dates

Recommendation

Keywords

Life Science, Diagnostics, Merger, Acquisition, Waters Corporation, Becton Dickinson, BD Biosciences, BD Diagnostic Solutions, Reverse Morris Trust, Synergies, Financial Outlook, Market Expansion, Bioseparations, Bioanalytical Characterization, Multiplex Diagnostics, Flow Cytometry, Mass Spectrometry, Liquid Chromatography, Healthcare Technology